Hinova Pharmaceuticals Inc.：The combination of HP518 tablets and anti-tumor drugs for the treatment of advanced prostate cancer has received the approval notice for clinical drug trials
November 25, 2025
Source: drugdu
61
People Finance News, November 24th: Hinova Pharmaceuticals Inc. (688302) announced on November 24th that recently, they received the "Drug Clinical Trial Approval Notice" issued by the Drug Evaluation Center of the National Medical Products Administration of China, approving the use of HP518 tablets in combination with anti-tumor drugs for the Phase IIB/II clinical trial for the treatment of advanced prostate cancer. As of now, HP518 tablets have been approved for clinical trials for advanced prostate cancer in China, Australia, and the United States respectively. Currently, there are no similar products approved for market launch domestically or internationally.
HP518 is an oral PROTAC drug independently developed by the company based on its core technology platform for protein degradation targeting complexes. It is designed to target and degrade the androgen receptor and is intended to be used in combination with anti-tumor drugs for the treatment of advanced prostate cancer.
https://finance.eastmoney.com/a/202511243573069661.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Multiple batches of quadrivalent influenza virus split vaccine have been sub-packaged and submitted for lot release approval; expected to be released to the market soon after approval December 12, 2025
- Ab&B Bio-Tech CO., LTD. JS Lyophilized Human Rabies Vaccine Initiates Phase III Clinical Trials December 12, 2025
- The ‘Sweetest’ HPV Vaccine Market is Gone | Haibin Interview December 12, 2025
- InnoCare Pharma announced that its first independently developed next-generation TRK inhibitor, zoletrazinib, has been approved for marketing in China December 12, 2025
- Is PD-1/VEGF dual antibody + ADC becoming the standard configuration? December 12, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
